Download PDFPDF
New EULAR/ACR 2019 SLE Classification Criteria: defining ominosity in SLE
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Correspondence on “New EULAR/ACR 2019 SLE Classification Criteria: defining ominosity in SLE” by Whittall Garcia et al
    • Sarah Dyball, Clinical Research Fellow in Rheumatology Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal & Dermatological Sciences, The University of Manchester
    • Other Contributors:
      • Mia Rodziewicz, Clinical Research Fellow in Rheumatology
      • Ben Parker, Consultant Rheumatologist
      • Ian N Bruce, Professor of Rheumatology

    We read with interest the study by Whittall Garcia and colleagues (1) which reports on the ominosity associated with an EULAR/ACR-2019 SLE classification score of 20 or greater.

    While the correlation of score and disease severity is interesting, they do not report any association with health-related quality of life. We applied the EULAR/ ACR-2019 criteria to a cross-sectional cohort of 103 patients with SLE (92.2% female) with a mean [SD] age and disease duration of 44.8 [12.8] years and 12.9 [10] years respectively, which have previously been described.(2, 3) Of these patients, 37 (36%) had a EULAR/ ACR-2019 score of ≥20; defining ‘high ominosity’. The SF-36 physical and mental components score were calculated, and normalised against the UK population. The mean [SD] physical and mental summary scores were reduced in this cohort (31.6 [16.0] and 45.3 [10.5], respectively). We found no difference in either score between those who scored ≥20 and those who scored <20, in the physical components score (OR 1.0, CI 0.98-1.04, p=0.67) and mental components score (OR 1.0, CI 0.95-1.04, p=0.85). This suggests that even though some patients may have a ‘less severe’ disease trajectory and fewer number of manifestations at baseline, their quality of life may, nevertheless, be impaired. We postulate that this may be related to the ‘illness identity’ associated with being diagnosed with a rare chronic health condition, and concern over the clinical consequences of this diseas...

    Show More
    Conflict of Interest:
    INB has received grant support from Genzyme/Sanofi, GSK, Roche and UCB; consulting fees from AstraZeneca, Eli Lilly, GSK, Merck Serono, UCB and ILTOO; and was a speaker for AstraZeneca, GSK and UCB. BP has received grant support from Genzyme/Sanofi and GSK, honoraria from Fresenius-Kabi and AbbVie and was a speaker for Eli Lilly and Roche. SD and MR have received grant support from UCB.